Jennifer Kelly Shepphird, PhD | Authors

Potassium Channel Blockers Show Promise as Treatment for Brain Tumors

August 31, 2015

Highly druggable ion channels, which are common therapeutic targets for heart disease and neurological conditions, may represent useful targets in cancer treatment as well, according to researchers from the University of California at San Francisco.

T Cells from Melanoma Lymph Nodes Show Promise for Adoptive Immunotherapy

July 20, 2015

T cells generated from tumor-draining lymph nodes of patients with stage III melanoma were shown to mediate protective immune responses in vivo in a melanoma xenograft model, according to a report published in the Journal of Immunotherapy.

Molecular Predictors May Help Determine Outcome for Melanoma Patients

June 18, 2015

MicroRNA (miRNA) profiling of samples from patients with metastatic melanoma who were treated with carboplatin/paclitaxel (CP) identified significantly higher expression of a specific microRNA (miR-659-3p) that was associated with longer progression-free survival (P = .008).

CIMAvax Lung Cancer Vaccine Coming to the US From Cuba

May 19, 2015

Cuba is well known in the US for high quality cigars and rum, but less widely appreciated is the innovative research carried out in Cuba’s Center for Molecular Immunology. That could change if clinical studies of the cancer vaccine CIMAvax go well.

Oncogenes Implicated in Rare Choroid Plexus Carcinoma

May 18, 2015

Initiation and progression of the rare and often fatal brain cancer, choroid plexus carcinoma (CPC), depends on the presence of genes transcription initiation factor TFIID subunit 12 (TAF12) and nuclear transcription factor Y (NFYC), both transcription factors that regulate the epigenome, and DNA repair and recombination protein RAD54-like (RAD54L), a component in DNA homologous repair.

Cognitive Computing with IBM’s Watson Tackles Oncology Data

May 13, 2015

Leading cancer institutes from across the country are collaborating with IBM Watson Health to use the power of cognitive computing to personalize cancer treatment, according to a statement by the company.

Lenvatinib for Renal Cell Carcinoma Meets Primary Endpoint in Phase II trial

February 02, 2015

Japanese drug maker Eisai announced that the multiple kinase inhibitor lenvatinib, alone and in combination with everolimus, has been shown to prolong progression-free survival (PFS) in patients with unresectable advanced or metastatic renal cell carcinoma (mRCC).